Peace Of Mind Accuracy

Only the Eversense E3 CGM System offers 6 months of exceptional accuracy with a single sensor.

The Science Behind Eversense E3’s Long-Term Exceptional Accuracy

Unique Fluorescent Technology

  • The Eversense® E3 Sensor uses fluorescent light technology to measure glucose in interstitial fluid.
  • The intensity of the fluorescent light signal rises and falls in proportion to the body’s glucose levels
  • There is no interference with glucose measurements from Vitamin C or acetaminophen.

florescent-img.png

WATCH "HOW IT WORKS" VIDEO

Feel Confident Knowing Eversense E3 Demonstrates Exceptional Accuracy1 Overall

Continuous glucose monitoring is not only about more readings. It is also about getting accurate alerts for current or upcoming low or high glucose events, consistently over the time of CGM system wear.

Exceptional Accuracy—Mard 8.5%

Highly accurate, also in the low glucose range.

  • The overall MARD of the Eversense® E3 CGM system is 8.5% with 87.3% of readings within 15 mg/dL or 15% of the reference values (YSI).
  • In the hypoglycaemic range (40–60 mg/dL) the MAD* gets even better at 7.5% with 91.6% of readings within 15/15.

ysiglucoserange.png

Stable Performance Up To 6 Months

Month by month, Eversense E3 has demonstrated exceptional accuracy and stable performance over the course of 180 days with a single sensor. Readings you can count on!

sensordays.png

Confirmed High Detection Rates

  • 94% of low glucose events were detected correctly and alerted (using Predictive Alert), comparing to the laboratory reference (YSI)
  • 99% of high glucose events were detected correctly and alerted (using Predictive Alert), comparing to the laboratory reference (YSI)
  • Maybe it’s time to consider activating the Predictive Alert feature in the Eversense App. Talk to your health care provider to help you with this setting

glucoseevents.png

* MAD (mg/dL) was calculated for glucose values ≤ 80 mg/dL.
1. Garg, S. K. et al. (2021). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics, 24(2), 1-9. DOI: 10.1089/dia.2021.0182

Helpful Tips

Make the most out of Eversense E3 exceptional accuracy

Data You Can Trust To Treat

Eversense E3, with an overall MARD of 8.5%, is indicated to be used for treatment decisions without a confirmatory fingerstick (see disclaimer). This provides another level of trust and confidence from your Eversense E3 System.

cycleicon.png

Calibrating Your Eversense E3 Is Needed to Ensure High Levels of Accuracy Over 6 Months

While factory calibration might be possible for transcutaneous sensors lasting up to 2 weeks, a long-term implantable sensor lasting up to 180 days, essentially 12 times longer, requires calibration. This ensures the high accuracy of your Eversense E3 CGM System over the entire 6 months.

Calibration_gea.png

The More Accurate Your BGM Meter Is For Calibrating E3, the Better Your CGM Performance

CONTOUR® NEXT BGM System has demonstrated highly accurate results2, going beyond the minimum accuracy requirements of the ISO 15197:2013.3

Are you sure your BGM meter does the same? If not, think about making a change today, for getting your E3 CGM system performance to its maximum potential.

fingerstickimage.png

2. CONTOUR®NEXT (Connected) BGMS User Guide, Rev. 05/19.
3. International Organization for Standardization. In vitro diagnostic test systems—Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. ISO 15197:2013.

E3 Community

Connect with us on social media and use #EversenseVibeTribe to join the
Eversense community and share your E3 experience!

We're here for you

Our Eversense team is dedicated and ready to provide the answers and support you need.

Community Testimonial.png

Was this content helpful?

Yes

Somewhat

No

Discover more Tips & Tricks

INCISION CARE >

Stay in the know with the Eversense E3 and get hel...

CALIBRATION >

Learn how to set up and calibrate your system to s...

SMART TRANSMITTER >

Find out how the Eversense E3 Smart Transmitter is...

TREND ARROWS AND TREATMENT DECISIONS >

Stay on top of your diabetes management knowing yo...

GLUCOSE DATA FOR YOU >

Access your In-App Reports in the Eversense App to...

LOW AND HIGH ALERTS, AND TARGETS >

The Eversense E3 CGM System is designed to provide...

PREDICTIVE AND RATE OF CHANGE ALERTS >

Even with the best management plan, diabetes can s...

SHARING DATA WITH OTHERS >

Keep tabs on your glucose levels over time and sha...

E3 LONG TERM EXCEPTIONAL ACCURACY >

There is no other CGM system available today to of...

EVENT LOG IN EVERSENSE

Taking care of family and friends, performing at w...

TRAVELLING WITH EVERSENSE

When getting ready for traveling with diabetes, th...

GET READY FOR YOUR NEXT E3 SENSOR

Preparing for your next sensor in advance will ens...

Back to Overview

 

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.